Press Releases

January 3, 2018
BOSTON, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that subsidiary Elobix AB has entered into an agreement with HealthCare Royalty Partners (HCR) to monetize its royalty rights under its license agreement with EA Pharma Co., Ltd.